Gencor reports positive results from body composition study

The company’s ActivAMP extract was associated with a significant fat reduction in males and females

Gencor has reported positive topline results from its body composition study in overweight male and female subjects. The study, which evaluated ‘class one’ obese subjects, found application of Gencor’s Gynostemma pentaphyllum extract (ActivAMP) resulted in improvement of body composition for overweight males and females aged over 18 years old.

The subjects, who were studied in a double-blind, randomised, clinical trial with a treatment duration of 16 weeks, experienced a significant reduction of visceral fat for males and a significant difference in gynoid fat for females, compared to a placebo.

“We are extremely pleased with our clinically meaningful study results on body composition,” said Chase Shyroc, Vice President of Sales & Business Development for Gencor. “In previous human, animal and phytochemical studies, ActivAMP has achieved a demonstrated effect on the metabolic process via AMPk activation. This recent study provides additional validation for Gencor’s weight management platform.”

Study subjects were provided with a daily dose of 450 mg (or two capsules daily) of ActivAMP for a period of 16 weeks. The placebo consisted of a maltodextrin housed in an opaque gel capsule, which was identical to the test product. The primary outcome measured was body fat via a dual-energy X-ray absorptiometry scan.

“Given the changes in both dietary and physical activity patterns of our society,” said Shyroc, “we must continue to research methods of complementing lifestyle modifications, such as diet and exercise. Gynostemma pentaphyllum has long been studied as a tool for management of healthy body composition because of its ability to reduce lipid and blood glucose levels.”

Companies